(sunitinib malate)
The recommended dosage of SUTENT for gastrointestinal stromal tumor (GIST) and advanced renal cell carcinoma (RCC) is 50 mg taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) until disease progression or unacceptable toxicity. SUTENT may be taken with or without food.
The recommended dosage of SUTENT for the adjuvant treatment of RCC is 50 mg taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2), for nine 6-week cycles. SUTENT may be taken with or without food.
The recommended dosage of SUTENT for pancreatic neuroendocrine tumors (pNET) is 37.5 mg taken orally once daily until disease progression or unacceptable toxicity. SUTENT may be taken with or without food.
To manage adverse reactions, the recommended dosage modifications are provided in Table 1. Table 2 provides the recommended dosage reductions of SUTENT for adverse reactions.
| Indications | GIST | RCC | pNET | |
|---|---|---|---|---|
| Advanced RCC | Adjuvant RCC | |||
First dose reduction | 37.5 mg once daily | 37.5 mg once daily | 37.5 mg once daily | 25 mg once daily |
Second dose reduction | 25 mg once daily | 25 mg once daily | NA | NA |
| Adverse Reaction | Severity | Dosage Modifications for SUTENT |
|---|---|---|
Hepatotoxicity [see Warnings and Precautions (5.1)] | Grade 3 |
|
Grade 4 |
| |
Cardiovascular events [see Warnings and Precautions (5.2)] | Asymptomatic cardiomyopathy (left ventricular ejection fraction greater than 20% but less than 50% below baseline or below the lower limit of normal if baseline was not obtained) |
|
Clinically manifested congestive heart failure (CHF) |
| |
Hypertension [see Warnings and Precautions (5.4)] | Grade 3 |
|
Grade 4 |
| |
Hemorrhagic events [see Warnings and Precautions (5.5)] | Grade 3 or 4 |
|
Thrombotic microangiopathy [see Warnings and Precautions (5.7)] | Any Grade |
|
Proteinuria or Nephrotic syndrome [see Warnings and Precautions (5.8)] | 3 or more grams proteinuria in 24 hours in the absence of nephrotic syndrome |
|
Nephrotic syndrome or recurrent proteinuria of 3 or more grams per 24 hours despite dose reductions |
| |
Dermatological toxicities Erythema multiforme (EM), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), Necrotizing fasciitis [see Warnings and Precautions (5.9)] | Any Grade |
|
Reversible posterior leukoencephalopathy syndrome [see Warnings and Precautions (5.10)] | Any Grade |
|
Osteonecrosis of the jaw [see Warnings and Precautions (5.13)] | Any Grade |
|
Impaired wound healing [see Warnings and Precautions (5.14)] | Any Grade |
|
Strong CYP3A4 Inhibitors
Select an alternate concomitant medication with no or minimal enzyme inhibition potential. If coadministration of SUTENT with a strong CYP3A4 inhibitor cannot be avoided, consider a dose reduction for SUTENT to a minimum dosage as follows [see Drug Interactions (7.1)]:
Strong CYP3A4 Inducers
Select an alternate concomitant medication with no or minimal enzyme induction potential. If coadministration of SUTENT with a strong CYP3A4 inducer cannot be avoided, consider a dose increase for SUTENT to a maximum dosage as follows:
If the dose of SUTENT is increased, monitor patients carefully for adverse reactions [see Drug Interactions (7.1)].
No starting dose adjustment is required in patients with end-stage renal disease (ESRD) on hemodialysis. However, given the decreased exposure compared to patients with normal renal function, subsequent doses may be increased gradually up to 2-fold based on safety and tolerability [see Clinical Pharmacology (12.3)].
| This Medication Guide has been approved by the U.S. Food and Drug Administration. Revised: October 2025 | ||
MEDICATION GUIDE | ||
What is the most important information I should know about SUTENT?
Your healthcare provider should do blood tests to check your liver function before you start taking and during treatment with SUTENT. Your healthcare provider may temporarily stop, reduce your dose, or permanently stop treatment with SUTENT if you develop liver problems. | ||
What is SUTENT?
It is not known if SUTENT is safe and effective in children. | ||
Before taking SUTENT tell your healthcare provider about all of your medical conditions, including if you:
Tell all of your healthcare providers and dentists that you are taking SUTENT. They should talk to the healthcare provider who prescribed SUTENT for you, before you have any surgery, or medical or dental procedure. Tell your healthcare provider about all the medicines you take, including prescription medicines and over-the-counter medicines, vitamins, and herbal supplements. Using SUTENT with certain other medicines can cause serious side effects. You may have an increased risk of severe jawbone problems (osteonecrosis) if you take SUTENT and a bisphosphonate medicine. Especially tell your healthcare provider if you are taking or have taken an osteoporosis medicine. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine. | ||
How should I take SUTENT?
| ||
What are possible side effects of SUTENT?
| ||
|
| |
| ||
|
| |
Your healthcare provider may prescribe medicine for you to treat high blood pressure, if needed. | ||
| ||
|
| |
| ||
|
| |
| ||
|
| |
Your healthcare provider may temporarily stop, reduce your dose, or permanently stop treatment with SUTENT if you develop serious side effects. Common side effects of SUTENT include: | ||
|
| |
The medicine in SUTENT is yellow, and it may make your skin look yellow. Your skin and hair may get lighter in color. SUTENT may also cause other skin problems including: dryness, thickness or cracking of the skin. These are not all of the possible side effects of SUTENT. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. | ||
How do I store SUTENT?
Keep SUTENT and all medicines out of the reach of children. | ||
General information about the safe and effective use of SUTENT. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use SUTENT for a condition for which it was not prescribed. Do not give SUTENT to other people, even if they have the same symptoms that you have. It may harm them. You can ask your healthcare provider or pharmacist for information about SUTENT that is written for health professionals. | ||
What are the ingredients in SUTENT? ![]() LAB-0361-13.0 | ||
Additional Resources
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine or vaccine.
Speak with a Pfizer Medical Information Professional regarding your Pfizer medicine or vaccine inquiry.
Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for a Pfizer medicine or a vaccine.
The submission will be reviewed during our standard business hours.
To report an adverse event related to a Pfizer product and you are not part of a clinical trial* for this medication, click the link below to submit your information:
Pfizer Safety Reporting Site
*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.
If you cannot use the above website to report an adverse event related to a Pfizer medication, please call (800) 438-1985.
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or by calling (800) 332-1088.